Table 1.
Characteristics of the study group. Data shown as mean values ± SD or medians (Q1–Q3).
| Age | 60 ± 11 |
|---|---|
| BMI (kg/m2) | 26.4 ± 4.2 |
| BMI ≥ 30, n (%) | 6 (15.4) |
| Metastasis: | |
| synchronous, n (%) | 14 (35.9) |
| metachronous, n (%) | 25 (64.1) |
| Metastasis to: | |
| one organ, n (%) | 9 (23.1) |
| multiple organs, n (%) | 30 (76.9) |
| Bone metastasis, n (%) | 21 (53.8) |
| Liver metastasis, n (%) | 14 (35.9) |
| Brain metastasis, n (%) | 4 (10.3) |
| Lung/pleural metastasis, n (%) | 20 (51.3) |
| Soft tissue metastasis/thoracic infiltration, n (%) | 11 (28.2) |
| Metastasis to the mediastinal and retroperitoneal lymph nodes, n (%) | 17 (43.6) |
| Grading | |
| 1, n (%) | 0 |
| 2, n (%) | 26 (66.7) |
| 3, n (%) | 9 (23.1) |
| no data n | 4 |
| Ki67, % | 34 ± 27 |
| EgR, n (%) | 28 (71.8) |
| PgR n (%) | 19 (48.7) |
| HER2, n (%) | 10 (25.6) |
| Biological subtypes of breast cancer: | |
| HR+/HER2−, n (%) | 26 (66.7) |
| HR−/HER2−, n (%) | 4 (10.3) |
| HR−/HER2+, n (%) | 5 (12.8) |
| HR+/HER2+, n (%) | 4 (10.3) |
| Hypertension, n (%) | 26 (66.7) |
| Diabates mellitus t.2, n (%) | 11 (28.2) |
| Bisphosphonates, n (%) | 12 (30.8) |
| Insulin therapy, n (%) | 2 (5.1) |
| Antithrombotic prophylaxis, n (%) | 14 (35.9) |
| Follow up, months | 23 (9–32) |
| The best first response to treatment: | |
| PD, n (%) | 15 (38.5) |
| SD, n (%) | 16 (41.0) |
| PR, n (%) | 8 (20.5) |
| PFS, months | 9 (4–34) |
| Observation time in the living patients, months | 32 (26–39) |
| Deaths, n (%) | 28 (71.8) |
| OS, months | 27 (14–44) |